from 27/08/13 ASX release - Gedeon Richter appointed to...

from 27/08/13 ASX release - Gedeon Richter appointed to commercialise estradiol skin spray therapy for female menopause symptoms in ex-US markets; Acrux has received US$1m and can earn further payments of US$2.6 million plus royalties on sales

KV Pharmaceutical, Acrux’s US licensee, is currently in Chapter 11 bankruptcy protection. Acrux expects the bankruptcy process to be resolved in the 2013/14 financial year, the outcome of which will determine Acrux’s future actions. US net sales are currently approximately US$10 million per annum.

if you look at subsequent ANNs I believe there will be something further there regarding the distribution rights to KV Pharmaceutical - due to there "situation".